Annales De Dermatologie Et De Venereologie最新文献

英文中文

A rare case of granular parakeratosis of the glans resembling genital psoriasis 一例罕见的类似生殖器银屑病的龟头颗粒状角化不全病例

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103268

A. Badaoui, I. Moulonguet

引用次数: 0

Electrosurgery in the treatment of pedunculated rhinophyma 电外科手术治疗有蒂鼻炎

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-26 DOI: 10.1016/j.annder.2024.103270

M. Dultra, P. Barros, A. Ivanchuk, J.R. Pegas

引用次数: 0

Real-life management of psoriasis with biological agents during pregnancy 孕期使用生物制剂治疗银屑病的实际情况

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-29 DOI: 10.1016/j.annder.2024.103254

C. Tran , E. Mahé , M. Beylot-Barry , D. Jullien , M.-A. Richard , A.-C. Fougerousse , A. Bouznad , C. Bulai Livideanu , A. Brun , F. Amelot , F. Maccari , F. Aubin , F. Benhadou , C. Paul

Background

French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.

Material and methods

We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.

Results

A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.

Discussion

The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.

背景法国指南建议，根据相关的产品特性摘要（SmPC），在受孕前 3 至 24 周停止银屑病的生物制剂治疗。本研究旨在评估皮肤科医生在治疗曾接受过生物制剂治疗的银屑病孕妇时的实际做法。材料与方法我们与 GRPso 和 Resopso 合作开展了一项研究。从业人员填写了一份电脑问卷。我们进行了描述性统计，并研究了从业人员的概况、他们对孕期继续使用生物制剂的信心程度以及他们报告的孕期使用生物制剂的做法。我们使用 XLSTAT 进行了统计分析。结果共有 63 名皮肤科医生（女性：71%；平均年龄 43.8 岁）参与了这项研究，其中大部分是医院医生（87%）。36.5%的医生遵循了建议，44%的医生在确诊怀孕后停用了生物制剂，20.5%的医生在怀孕期间使用了这些制剂。在拥有十年以上经验的皮肤科医生中，19% 的医生表示遵循了 SmPC 的建议。在拥有 200 名患者（使用生物制剂治疗银屑病的患者）的皮肤科医生中，19% 的医生表示遵循 SmPC，而在拥有不到 50 名患者的皮肤科医生中，54% 的医生表示遵循 SmPC。讨论大多数皮肤科医生没有遵循在患者计划怀孕前停用生物制剂的建议。

{"title":"Real-life management of psoriasis with biological agents during pregnancy","authors":"C. Tran , E. Mahé , M. Beylot-Barry , D. Jullien , M.-A. Richard , A.-C. Fougerousse , A. Bouznad , C. Bulai Livideanu , A. Brun , F. Amelot , F. Maccari , F. Aubin , F. Benhadou , C. Paul","doi":"10.1016/j.annder.2024.103254","DOIUrl":"https://doi.org/10.1016/j.annder.2024.103254","url":null,"abstract":"<div><h3>Background</h3><p>French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.</p></div><div><h3>Material and methods</h3><p>We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.</p></div><div><h3>Results</h3><p>A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.</p></div><div><h3>Discussion</h3><p>The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140328083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of rituximab use over time in moderate-to-severe pemphigus: A two-centre retrospective study 中重度丘疹性荨麻疹患者使用利妥昔单抗的演变：一项双中心回顾性研究

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-28 DOI: 10.1016/j.annder.2024.103265

M. Hazard, C. Bedane, O. Ducharme, P. Bernard, A.-L. Pham-Ledard

引用次数: 0

Pemphigoid of the pulmonary system 肺部系统丘疹性脓疱病

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-28 DOI: 10.1016/j.annder.2024.103253

A.R. Ahmed, M. Kalesinskas

引用次数: 0

Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients 用利妥昔单抗维持治疗丘疹性荨麻疹的实际效果：对50名患者进行的单中心研究

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-26 DOI: 10.1016/j.annder.2024.103264

A. Louchez , T. El Aarbaoui , A. Weill , O. Gaudin , L. Jelti , T. Belmondo , P. Wolkenstein , S. Ingen-Housz-Oro

Background

Following the RITUX 3 therapeutic trial, the French national diagnosis and care protocol (NDCP) for the treatment of pemphigus was updated in 2018. The updated protocol recommends initial treatment with rituximab (RTX) followed by maintenance therapy at 12 and 18 months, and potentially at 6 months where there are risk factors for early relapse. We evaluated these recommendations regarding the management of our own patients.

Patients and Methods

Our single-center retrospective study included all patients with pemphigus diagnosed between 01/2015 and 10/2020 and receiving at least one initial infusion of RTX. We collected the following data: type of pemphigus, severity, levels of anti-desmoglein 1 and 3 antibodies at diagnosis and between 2 and 6 months after initial RTX, presence or absence of maintenance therapy and modalities, time to first relapse and duration of associated systemic corticosteroid therapy ≥5 mg/day. Maintenance treatment modalities were as follows: no maintenance treatment, maintenance “on demand” (MT1) i.e. not performed at the rate imposed by the NDCP, and maintenance “according to NDCP” (MT2).

Results

Fifty patients were included (women 54%, median age 58 years, pemphigus vulgaris 68%, moderate to severe 68%). Initial RTX was combined with systemic corticosteroid therapy at 0.5 to 1 mg/kg in 74% of cases. Twenty-seven patients (54%) received no maintenance therapy, 13 were on an MT1 regimen (26%), and 10 were on an MT2 regimen (20%). Median follow-up was 42 months. At the last follow-up, 39 patients (78%) were in complete remission. A total of 25 patients (50%) relapsed: 18/27 (67%) patients without maintenance, 5/13 (38%) with MT1, and 2/10 (20%) with MT2 (p = 0.026). The probability of relapse over time was significantly lower in patients receiving maintenance therapy compared to those who receiving none (p = 0.022). The median time to relapse was 15 months in patients without maintenance, and 30 and 28 in those with maintenance (p = 0.27). The median duration of systemic corticosteroid therapy ≥ 5 mg/day in the no-maintenance group was 10 months, compared to 7 and 9 months respectively in MT1 and MT2 (p = 0.91).

Conclusion

Our study confirms the value of RTX maintenance therapy in pemphigus in real life.

背景在 RITUX 3 治疗试验之后，法国于 2018 年更新了治疗丘疹性荨麻疹的国家诊断和护理方案（NDCP）。更新后的方案建议使用利妥昔单抗（RTX）进行初始治疗，然后在12个月和18个月时进行维持治疗，如果存在早期复发的风险因素，则可能在6个月时进行维持治疗。患者和方法我们的单中心回顾性研究纳入了 2015 年 1 月 1 日至 2020 年 10 月 10 日期间确诊并接受至少一次 RTX 初始输注的所有丘疹性荨麻疹患者。我们收集了以下数据：丘疹性荨麻疹的类型、严重程度、诊断时和首次RTX治疗后2至6个月内抗去甲斑鸠蛋白1和3抗体的水平、有无接受维持治疗和治疗方式、首次复发的时间以及相关系统皮质类固醇治疗≥5毫克/天的持续时间。维持治疗模式如下：无维持治疗、"按需 "维持治疗（MT1），即不按NDCP规定的速度进行维持治疗，以及 "根据NDCP "维持治疗（MT2）。结果纳入了50名患者（女性54%，中位年龄58岁，寻常型天疱疮68%，中重度68%）。在 74% 的病例中，初始 RTX 与 0.5 至 1 mg/kg 的全身皮质类固醇治疗相结合。27名患者（54%）未接受维持治疗，13名患者采用MT1疗法（26%），10名患者采用MT2疗法（20%）。中位随访时间为 42 个月。在最后一次随访中，39 名患者（78%）病情完全缓解。共有 25 名患者（50%）复发：18/27（67%）名患者未接受维持治疗，5/13（38%）名患者接受 MT1 治疗，2/10（20%）名患者接受 MT2 治疗（P = 0.026）。与未接受维持治疗的患者相比，接受维持治疗的患者随着时间推移的复发概率明显降低（p = 0.022）。未接受维持治疗患者的中位复发时间为 15 个月，接受维持治疗患者的中位复发时间分别为 30 个月和 28 个月（p = 0.27）。未接受维持治疗组患者全身皮质类固醇治疗的中位持续时间≥5 mg/天，为10个月，而MT1和MT2患者分别为7个月和9个月（p = 0.91）。

{"title":"Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients","authors":"A. Louchez , T. El Aarbaoui , A. Weill , O. Gaudin , L. Jelti , T. Belmondo , P. Wolkenstein , S. Ingen-Housz-Oro","doi":"10.1016/j.annder.2024.103264","DOIUrl":"https://doi.org/10.1016/j.annder.2024.103264","url":null,"abstract":"<div><h3>Background</h3><p>Following the RITUX 3 therapeutic trial, the French national diagnosis and care protocol (NDCP) for the treatment of pemphigus was updated in 2018. The updated protocol recommends initial treatment with rituximab (RTX) followed by maintenance therapy at 12 and 18 months, and potentially at 6 months where there are risk factors for early relapse. We evaluated these recommendations regarding the management of our own patients.</p></div><div><h3>Patients and Methods</h3><p>Our single-center retrospective study included all patients with pemphigus diagnosed between 01/2015 and 10/2020 and receiving at least one initial infusion of RTX. We collected the following data: type of pemphigus, severity, levels of anti-desmoglein 1 and 3 antibodies at diagnosis and between 2 and 6 months after initial RTX, presence or absence of maintenance therapy and modalities, time to first relapse and duration of associated systemic corticosteroid therapy ≥5 mg/day. Maintenance treatment modalities were as follows: no maintenance treatment, maintenance “on demand” (MT1) <em>i.e.</em> not performed at the rate imposed by the NDCP, and maintenance “according to NDCP” (MT2).</p></div><div><h3>Results</h3><p>Fifty patients were included (women 54%, median age 58 years, pemphigus vulgaris 68%, moderate to severe 68%). Initial RTX was combined with systemic corticosteroid therapy at 0.5 to 1 mg/kg in 74% of cases. Twenty-seven patients (54%) received no maintenance therapy, 13 were on an MT1 regimen (26%), and 10 were on an MT2 regimen (20%). Median follow-up was 42 months. At the last follow-up, 39 patients (78%) were in complete remission. A total of 25 patients (50%) relapsed: 18/27 (67%) patients without maintenance, 5/13 (38%) with MT1, and 2/10 (20%) with MT2 (<em>p</em> = 0.026). The probability of relapse over time was significantly lower in patients receiving maintenance therapy compared to those who receiving none (<em>p</em> = 0.022). The median time to relapse was 15 months in patients without maintenance, and 30 and 28 in those with maintenance (<em>p</em> = 0.27). The median duration of systemic corticosteroid therapy ≥ 5 mg/day in the no-maintenance group was 10 months, compared to 7 and 9 months respectively in MT1 and MT2 (<em>p</em> = 0.91).</p></div><div><h3>Conclusion</h3><p>Our study confirms the value of RTX maintenance therapy in pemphigus in real life.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140290884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resolution of refractory single-nail psoriasis through a single session of fractional CO2 laser-asssited methotrexate delivery 通过单次点阵二氧化碳激光辅助甲氨蝶呤给药治疗难治性单甲银屑病

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-20 DOI: 10.1016/j.annder.2024.103255

B. Soutou , J. Kaikati , R. Afiouni, R. Jabbour, S. Skaff, J Abou Khater, J. Helou

引用次数: 0

Retaining dermatology patients in primary care through dialogue with secondary care providers: A service evaluation 通过与二级医疗机构的对话，将皮肤科患者留在基层医疗机构：服务评估

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-20 DOI: 10.1016/j.annder.2024.103248

J. Brainard , A. Crawford , B. Wright , M. Lim , P. Everden

Background

There are long patient waiting lists for specialist care. A dermatology dialogue service between primary and secondary care (DDPS) was developed in eastern England. Primary care referrers uploaded patient images of skin conditions for review by and dialogue with consultant dermatologists in an attempt to retain patients in primary care rather than refer them to secondary care.

Methods

Evaluation of service performance against specific targets, including reduction in secondary care waiting list growth over the period April 2021–March 2022 inclusive. Service activity was summarized in terms of speed of resolution, case numbers, and dispositions. Clinician and patient satisfaction were assessed using structured questionnaires. Actual numbers of new referrals were compared to projections based on historical data. Waiting list growth was compared to other specialties and other commissioning areas. Waiting times to initial treatment were monitored.

Results

Over 3300 patients were enrolled and > 90% of dialogues were resolved within 36 hours. Clinician and patient satisfaction were high. Frequently asked questions and conditions were highlighted by dermatologists to design and deliver an educational event for primary care clinicians that was well received. Waiting list growth for dermatology patients in the commissioning area was smaller than for other major specialties, and generally smaller than growth for dermatology waiting lists commissioned by other NHS commissioners. There was no negative impact on the urgent priority (cancer pathway) waiting list.

Conclusion

The DDPS was satisfactory for clinicians and patients and coincided with lower growth in dermatology waiting lists than might otherwise have been expected.

背景病人等待专科治疗的时间很长。英格兰东部开发了一项初级和二级医疗之间的皮肤病对话服务（DDPS）。初级医疗转诊者上传患者皮肤状况的图片，供皮肤科顾问医生查看并进行对话，试图将患者留在初级医疗机构，而不是转诊到二级医疗机构。方法对照特定目标对服务绩效进行评估，包括在 2021 年 4 月至 2022 年 3 月（含 2022 年 3 月）期间减少二级医疗机构候诊人数的增长。根据解决速度、病例数量和处理情况对服务活动进行总结。使用结构化问卷对临床医生和患者的满意度进行评估。新转诊的实际数量与基于历史数据的预测进行了比较。将候诊人数增长情况与其他专科和其他委托领域进行比较。对初始治疗的等待时间进行了监测。结果有 3300 多名患者登记，90% 的对话在 36 小时内得到解决。临床医生和患者的满意度都很高。皮肤科医生着重强调了常见问题和病情，为初级保健临床医生设计并举办了一次教育活动，受到了广泛欢迎。委托区域内皮肤科患者候诊名单的增长幅度低于其他主要专科，总体上也低于其他 NHS 委托方皮肤科候诊名单的增长幅度。结论：DDPS 对临床医生和患者来说都是令人满意的，同时皮肤科候诊人数的增长也低于预期。

{"title":"Retaining dermatology patients in primary care through dialogue with secondary care providers: A service evaluation","authors":"J. Brainard , A. Crawford , B. Wright , M. Lim , P. Everden","doi":"10.1016/j.annder.2024.103248","DOIUrl":"https://doi.org/10.1016/j.annder.2024.103248","url":null,"abstract":"<div><h3>Background</h3><p>There are long patient waiting lists for specialist care. A dermatology dialogue service between primary and secondary care (DDPS) was developed in eastern England. Primary care referrers uploaded patient images of skin conditions for review by and dialogue with consultant dermatologists in an attempt to retain patients in primary care rather than refer them to secondary care.</p></div><div><h3>Methods</h3><p>Evaluation of service performance against specific targets, including reduction in secondary care waiting list growth over the period April 2021–March 2022 inclusive. Service activity was summarized in terms of speed of resolution, case numbers, and dispositions. Clinician and patient satisfaction were assessed using structured questionnaires. Actual numbers of new referrals were compared to projections based on historical data. Waiting list growth was compared to other specialties and other commissioning areas. Waiting times to initial treatment were monitored.</p></div><div><h3>Results</h3><p>Over 3300 patients were enrolled and > 90% of dialogues were resolved within 36 hours. Clinician and patient satisfaction were high. Frequently asked questions and conditions were highlighted by dermatologists to design and deliver an educational event for primary care clinicians that was well received. Waiting list growth for dermatology patients in the commissioning area was smaller than for other major specialties, and generally smaller than growth for dermatology waiting lists commissioned by other NHS commissioners. There was no negative impact on the urgent priority (cancer pathway) waiting list.</p></div><div><h3>Conclusion</h3><p>The DDPS was satisfactory for clinicians and patients and coincided with lower growth in dermatology waiting lists than might otherwise have been expected.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0151963824000048/pdfft?md5=a2e26bab035b177309de519f6fc54fc4&pid=1-s2.0-S0151963824000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of dupilumab for atopic dermatitis in a renal transplant patient 杜必鲁单抗治疗肾移植患者特应性皮炎的有效性和安全性

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-19 DOI: 10.1016/j.annder.2024.103259

T. Randriamiarana, D. Boutin, A. Thierry, J.-C. Lecron, E. Hainaut, M. Masson Regnault

引用次数: 0

Palbociclib-induced subacute cutaneous lupus erythematosus 帕博西尼诱发的亚急性皮肤红斑狼疮

IF 0.9 4区医学 Q3 Medicine

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-19 DOI: 10.1016/j.annder.2024.103260

A. Carrasquilla-Capilla, L. Crumbach, A. Neuhart, M. Amini-Adle

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀